Literature DB >> 15607360

High Th1/Th2 ratio in patients with multiple myeloma.

Hatsue Ogawara1, Hiroshi Handa, Tohru Yamazaki, Takuma Toda, Kensuke Yoshida, Natsumi Nishimoto, Wedad Hamdi Saleh Al-ma'Quol, Yoriaki Kaneko, Takafumi Matsushima, Norifumi Tsukamoto, Yoshihisa Nojima, Morio Matsumoto, Morio Sawamura, Hirokazu Murakami.   

Abstract

To determine the clinical significance of the T helper 1(Th1)/T helper 2 (Th2) ratio in multiple myeloma, the intracellular IFN-gamma and IL-4 were analyzed by flow cytometry in 56 patients with multiple myeloma. The mean Th1/Th2 ratio of cases in the initial diagnosis phase and the refractory phase were higher than that of the control group. The mean serum beta-2-microglobulin in the high Th1/Th2 subgroup was significantly higher than that in the normal Th1/Th2 subgroup (P < 0.05). In conclusion, the Th1/Th2 ratio was closely related to the disease status of multiple myeloma.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15607360     DOI： 10.1016/j.leukres.2004.06.003

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  28 in total

1.  Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial.

Authors:  Andrew R Branagan; Eamon Duffy; Randy A Albrecht; Dennis L Cooper; Stuart Seropian; Terri L Parker; Geliang Gan; Fangyong Li; Daniel Zelterman; Chandra Sekhar Boddupalli; Lin Zhang; Rakesh Verma; Thomas M Ferencz; Madhav V Dhodapkar
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-03-07

2.  Clinical significance of cancer-related fatigue in multiple myeloma patients.

Authors:  Kazuhito Suzuki; Nobuyuki Kobayashi; Yoji Ogasawara; Takaki Shimada; Yuichi Yahagi; Katsuki Sugiyama; Shinobu Takahara; Takeshi Saito; Jiro Minami; Hiroki Yokoyama; Yutaro Kamiyama; Atsushi Katsube; Kazuhiro Kondo; Hiroyuki Yanagisawa; Keisuke Aiba; Shingo Yano
Journal:  Int J Hematol       Date:  2018-08-28       Impact factor: 2.490

3.  Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut.

Authors:  Kyoung-Mu Lee; Dalsu Baris; Yawei Zhang; H Dean Hosgood; Idan Menashe; Meredith Yeager; Shelia Hoar Zahm; Sophia S Wang; Mark P Purdue; Stephen Chanock; Tongzhang Zheng; Nathaniel Rothman; Qing Lan
Journal:  Am J Hematol       Date:  2010-08       Impact factor: 10.047

Review 4.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

Review 5.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

Review 6.  Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?

Authors:  Myo Htut
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 3.952

Review 7.  Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Authors:  Ivetta Danylesko; Katia Beider; Avichai Shimoni; Arnon Nagler
Journal:  Clin Dev Immunol       Date:  2012-05-10

Review 8.  Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.

Authors:  Liu Zhaoyun; Fu Rong
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

9.  Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma.

Authors:  Roberta Martiniani; Valentina Di Loreto; Chiara Di Sano; Alessandra Lombardo; Anna Marina Liberati
Journal:  Adv Hematol       Date:  2012-08-02

10.  Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma.

Authors:  Jae-Sook Ahn; Sung Yoon Rew; Deok-Hwan Yang; Sung-Hoon Jung; Seung-Ji Kang; Mi-Young Kim; Seung-Shin Lee; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Blood Res       Date:  2013-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.